Back to search

University of South Florida

Effect of dual inhibition of atypical PKC signaling and PI3K/Akt signaling on cell viability and apoptosis in clear cell Renal Cell Carcinoma (ccRCC).

Abstract

dc:description

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer (85%); 75% of the cases involve conventional clear cell RCC (ccRCC). The choice of treatments recommended for clear cell carcinoma and non-clear cell carcinoma include partial nephrectomy (Stage I), radical nephrectomy (Stages II and III), and chemotherapy (stage IV). Phosphatidylinositol-3-kinase (PI3K) inhibitors can be a viable candidate in the chemotherapy of ccRCC because the PI3K/Akt pathway is frequently activated in RCC. Hence, PI3K inhibitors like Alpelisib (BYL719) can be chosen as a treatment. In addition, aPKCs (PKC-ί and PKC ζ) are overexpressed in most cancer cells, and they play a central role in tumor progression and the metastasis of different types of cancers. Treatment of ccRCC metastatic clear cells with a combination of aPKC inhibitor ICA-1 and BYL 719 inhibits PKC-ί and it also causes the downstream inhibition of c-Myc. Inhibition of the aPKCs (PKC ί) also reduces the activation of other important proteins, such as Mitogen-Activated Protein Kinase Kinase (MEK) and extracellular signal-regulated kinase (ERK1/2). It is observed that treatment with ICA-1 disrupts the level of the aPKC-Akt1 association, which, in turn, reduces the activation of Akt1 through phosphorylation. ICA-1 treatment also disrupts the association between aPKC and c-Myc. The inhibition of aPKCs and other downstream effector proteins by combination therapy is more pronounced compared to a single therapy. These effects contribute to reduced cell growth, cell survival, and, eventually, the induction of apoptosis. The wound healing assay and the Boyden Chamber assay also suggested that there is decreased invasiveness of the cells when treated with the combination treatment. This can occur due to the inactivation of both ERK1/2 and Akt by the combination treatment. The decreased level of N-cadherin, p-vimentin, and vimentin and the increased level of E-cadherin confirm reduced malignancy. Therefore, implementing a combination of Alpelisib and an aPKC inhibitor is an effective approach to reducing cell proliferation, invasion, and resistance that eventually induces apoptosis.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (Ph.D.)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Chemistry
Grantor
University of South Florida
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Khalid, Khandker M.
Contributors dc:contributor
  • Mildred Acevedo-Duncan, Ph.D.
  • Ioannis Gelis, Ph.D.
  • Edward Turos, Ph.D.
  • Meera Nanjundan, Ph.D.

Subjects

dc:subject × 7

Identifiers

dc:identifier.*
Repository record dc:identifier
https://digitalcommons.usf.edu/etd/10784

Chain of custody

source
Harvested from
University of South Florida
Base URL
digitalcommons.usf.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Khalid, Khandker M.. Effect of dual inhibition of atypical PKC signaling and PI3K/Akt signaling on cell viability and apoptosis in clear cell Renal Cell Carcinoma (ccRCC).. Dissertation thesis, University of South Florida, 2023. https://digitalcommons.usf.edu/etd/10784